Fully human monoclonal neutralizing antibody for resisting novel coronavirus and application of fully human monoclonal neutralizing antibody

A monoclonal, antibody technology, used in antiviral agents, antiviral immunoglobulins, applications, etc., can solve the problems of infection risks of other diseases, inability to be widely used, and large differences between batches.
CN112794899AActive Publication Date: 2021-05-14SUZHOU YUZHIBO BIOLOGICAL TECH CO LTD
5 Cites 11 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
SUZHOU YUZHIBO BIOLOGICAL TECH CO LTD
Publication Date
2021-05-14

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the field of biological medicine, and discloses a fully human monoclonal neutralizing antibody for resisting novel coronavirus and application of the fully human monoclonal neutralizing antibody. B-type lymphocytes are screened from blood of a new coronal pneumonia rehabilitation patient, and the affinity constant of the obtained antibody and a virus receptor binding domain (RBD) is 1.19 nM. X-ray crystal diffraction is used for analyzing the three-dimensional structure of the antibody and RBD compound, it is found that the binding epitope of the antibody and the binding epitope of a host cell receptor (ACE2) are highly overlapped, binding of the RBD and the ACE2 can be competitively blocked, and infection of the RBD and the ACE2 is inhibited. The antibody can cope with certain genetic mutations of viruses, the half effective concentration of the antibody for blocking pseudoviruses (accumulated B.1. 1.7 mutant strain genes and D614G) from infecting host cells is 0.57 ng / mL, and the antibody has the advantages of safety, high efficiency and broad spectrum, and is expected to be used as a neutralizing antibody drug for diagnosing, treating and preventing new coronal pneumonia.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of biomedicine, in particular to a fully human monoclonal neutralizing antibody against novel coronavirus and its application. Background technique

[0002] The causative agent of novel coronavirus pneumonia (CoVID-19) is a novel coronavirus (SARS-CoV2), which can cause severe acute respiratory disease. According to the report of the World Health Organization, the epidemic has spread to all parts of the world, causing a large number of casualties. Clinical features of COVID-19 include fever, dry cough and fatigue, respiratory failure, and even death. So far, most of the vaccines and therapeutic drugs against COVID-19 are still in clinical trials and initial emergency trials, and their safety and effectiveness need further verification.

[0003] SARS-CoV2 belongs to the genus Coronavirus of the Coronaviridae family, and is a class of enveloped single-stranded positive-sense RNA viruses. The new coronavirus gene enco...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More